May 23, 2013
The company took the second place for its commitment in ensuring that families in the region receive high quality products, information and services.
The recognition was handed over at the Mother, Baby and Child Magazine awards ceremony held in Dubai last week.
The first of its kind awards ceremony was attended by dignitaries, influential guests and top 10 Mumtrepreneurs. Awards in 35 different categories were given away during the ceremony.
In his comments, Intikhab Alam, Head of Marketing at Masafi, said, "It is a matter of immense pride for Masafi to have won this top honour at the Mother, Baby & Child awards. The unprecedented success of Masafi water over the last three and half decades is driven by our commitment to provide world-class quality pure, natural...
May 22, 2013
Quintiles is the industry leader that best differentiates itself on service quality in Phase II/III clinical research, according to 157 pharmaceutical and biotechnology professionals who responded to Industry Standard Research’s (ISR) 2013 CRO Quality Benchmarking Report – Phase II/III. Respondents also rated Quintiles as the leader among large CROs for customer loyalty, defined by overall satisfaction, willingness to recommend and likelihood to use Quintiles again.
“We are deeply committed to helping our customers increase their probability of success at every stage of the product lifecycle,” said Paula Brown Stafford, President,"......Continue Reading >
May 22, 2013
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that results from a prospective, multicenter, randomized, controlled clinical trial show that endoscopic ablation therapy using the Barrx™ RF Ablation System is effective at eliminating Barrett’s esophagus, a pre-cancerous condition of the esophagus, and preventing disease progression.
The SURF Trial* (SUrveillance vs. RadioFrequency ablation) included 136 patients with Barrett’s esophagus containing confirmed"...Continue Reading >
May 21, 2013
For Media outside the U.S., Canada and UK
In patients with symptomatic asthma despite at least ICS/LABA therapy, tiotropium delivered by the Respimat® SoftMistTM Inhaler increases time to first severe exacerbation"...Continue Reading >
May 21, 2013
After years of low productivity, R&D in leading pharmaceutical and biotech companies is starting to deliver on its promises; the number of New Molecular Entities (NMEs) approved by the US FDA has leveled out and biotech companies’ share prices are rising, indicating profitable business models. Now is the time for launch. Arthur D. Little’s (ADL) latest viewpoint, ‘Launch excellence for new medicines,’ assesses the key success factors for the successful launch of new medicines.
According to ADL’s most recent project experience, launch"...Continue Reading >
May 17, 2013
Kinetic Concepts, Inc. announced today that ABThera™ Open Abdomen Negative Pressure Therapy System (ABThera™ OA NPT) was associated with significantly improved patient outcomes compared to traditional Barker’s vacuum-packing technique (BVPT) in trauma and surgical patients studied. Results of the observational study, “Prospective Study Examining Clinical Outcomes Associated with a Negative Pressure Wound Therapy System and Barker’s Vacuum Packing Technique” were published"...Continue Reading >
May 17, 2013
Quintiles today announced the completion of its initial public offering of 27,236,841 shares of its common stock at a price to the public of $40.00 per share. Quintiles offered and sold 13,125,000 shares of common stock in the offering and selling shareholders offered and sold 14,111,841 shares of common stock in the offering, including 3,552,631 shares that were offered and sold by the selling shareholders pursuant to the full exercise of the underwriters’ option to purchase additional shares.
Morgan Stanley, Barclays and J.P. Morgan served as joint book-running"...Continue Reading >
May 16, 2013
Growing body of clinical data supports superiority of the irreversible ErbB Family Blocker afatinib* over standard chemotherapy (with combination of cisplatin and gemcitabine or pemetrexed) for first-line treatment of patients with EGFR-mutation positive advanced NSCLC
First set of Phase III results unveiled from LUME-Lung clinical trial programme investigating triple angiokinase inhibitor nintedanib* in advanced NSCLC
2013 ASCO Annual Meeting
...Continue Reading >
May 16, 2013
Merck Serono, a division of Merck, Darmstadt, Germany, and Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, today announced a new, five-year clinical development agreement. This strategic collaboration is the first-of-its-kind between a biopharmaceutical company and a biopharmaceutical services provider, creating a comprehensive process that integrates the expertise and experience from both organizations into a single, well-aligned clinical development engine.
In a novel approach to clinical development that is founded on a shared commitment to cost-disciplined science, the collaboration is intended to optimize productivity in the design and execution"...Continue Reading >
May 15, 2013
New evidence presented on Wednesday 15th May 2013 at the European Wound Management Association (EWMA)’s conference in Copenhagen, revealed that elevated protease activity (EPA) was detected in almost half the wounds (43%) that resulted in skin graft failure1.
In the thirty patient study carried out and presented by Prof. Franck Duteille MD, Head of Department of Plastic Reconstructive and Aesthetic Surgery, University Hospital, Nantes, France, three out of four (75%) split thickness skin grafts failed in wounds that tested positive for EPA immediately prior to performing the graft procedure1 . This confirms EPA"......Continue Reading >
Most Popular Articles